International Journal of Hematology and Blood Disorders

Anemia due to Chronic Kidney Disease (CKD) represents a major portion of hemodynamic imbalance in dogs. Although the pathogenesis of the anemia in CKD is multifactorial, decreased production of erythropoietin by the diseased kidneys has been proven and the severity of anemia correlates positively with serum creatinine concentrations in affected dogs.

Therapeutic whole and Packed Red Blood Cell transfusion has always been a main stay in practice. However, the unavailability of appropriate dog donors, blood typing modalities and occurrence of post transfusion reactions are the common hurdles encountered. Alternatively, Darbepoetin alfa, a hyperglycosylated synthetic recombinant erythropoietin which is commonly used in human patients with CKD induced anemia is used in recent canine practice. Unlike human transfusion medicine, not much of study has been documented in dogs in India. However anecdotally, darbepoetin is perceived to less likely form antibodies compared to erythropoietin. A study comprising of 21 dogs referred to Madras Veterinary College Teaching Hospital (MVCTH) with CKD (stage II, III & IV were 7, 9 & 5 respectively) of multifactorial etiology during the period of January to December 2017 was done. Injectable Darbepoetin was administered @0.5μg/kg subcutaneously once in a week for three weeks along with supplementation of Iron to achieve a medium hematocrit of 30%. Efficacy of Darbepoetin was evaluated by measuring pre and post therapeutic clinico pathological studies. Darbepoetin proved effective in increasing PCV, anemic crisis potentially in 66.7% of dogs. Hypertension, vomiting, melena, inappetance were common findings in affected dogs and coexistence of normocytic, normochromic progressive anemia which responds to Darbepoetin alfa therapy. Though expensive than Erythropoietin, Darbepoetin @0.5μg/kg s/c proved safe and effective in improving packed cell volume in CKD dogs as an alternative to packed RBC or whole blood transfusion. Further immunological, toxicological and clinical studies on Darbepoetin therapy is warranted in a large population in dogs.

Keywords: Ckd; Azotemia; Anemia; Darbepoetin

Canine kidney disease is the most common cause of morbidity and mortality in dogs. In Chronic Kidney Disease (CKD), irreversible and progressive damage to the kidneys results in excretory, fluid, acid-base and electrolyte abnormalities leading to accumulation of metabolic waste substances like BUN and Creatinine (Grauer, 2017). Kidney is the primary source of erythropoietin, which is responsible for the production of RBC from bone marrow. But in CKD dogs, gradual reduction in functional mass may leads to deficiency of erythropoietin ends up with anemia. Darbepoetin alfa, a hyperglycosylated synthetic recombinant erythropoietin analog is commonly used in human patients with CKD induced anemia (Polzin, 2013). Efficacy and role of Darbepoetin was not much evaluated in dogs in India, hence present study was conducted to assess the severity of anemia in CKD dogs and to assess the efficacy of Darbepoetin in anaemic dogs with CKD.

Chronic kidney disease (CKD) is a metabolic disorder of companion animals, estimated to occur in 0.4–1.5% of dogs and represented in a higher percentage of older dogs and those evaluated at tertiary care facilities.( O’Neil,2013).

A progressive, normocytic, normochromic hypo proliferative anemia develops as a feature of CKD, and although there are no published data on the prevalence of anemia in dogs with CKD, it is expected to occur in most dogs that progress to end‐stage disease. (Cowgill, 2013 and Bartges, 2012)

In addition to contributing to lethargy, anorexia, and weakness, severe anemia may exacerbate progression of CKD because of decreased oxygen delivery to the residual kidney. (Chakrabarti, 2012)

Egrie et al, 2003 reported that erythropoiesis‐stimulating agents (ESA) are administered to some dogs with anemia secondary to CKD. Epoetin alfa (epoetin) was the first ESA used in human and veterinary medicine, but it has largely been replaced by darbepoetin alfa (darbepoetin) due to a 3‐fold longer half‐life, allowing for less frequent dosing.

Twenty one dogs of different breeds and age groups were presented to Madras Veterinary College Teaching Hospital, Chennai with CKD (IRIS, 2017) (stage II , III & IV were 7, 9 & 5 respectively) of multifactorial etiology during the period of January 2017 to December 2017 were studied. Darbepoetin was administered @0.5μg/kg subcutaneously once in a week for four weeks along with supplementation of Iron injection to achieve a medium hematocrit of 30%. Efficacy of Darbepoetin was evaluated by clinical and hematological studies.

Pre therapeutic hemoglobin (g/dl), PCV (%) and Total erythrocytic counts (m/cmm) were 10.7, 32.4 & 4.1 (Stage II), 9.1, 24.1 & 3.42 (Stage III) and 7.9, 20.3 & 3.21 (Stage IV) respectively. Post therapeutic hematological parameters were depicted in table 3. Darbepoetin proved effective in increasing PCV, anemic crisis potentially in 66.7% of dogs. Hypertension, vomiting, melena, inappetance were common findings in affected dogs and coexistence of normocytic, normochromic progressive anemia which responds to Darbepoetin alfa therapy. Though expensive than Erythropoietin, Darbepoetin @0.5μg/kg s/c proved safe and effective in improving packed cell volume in CKD dogs as an alternative to packed RBC or whole blood transfusion.

Five dogs under study showed no much response to the administered Darbepoetin and underwent Packed RBC transfusions transiently. Four of these dogs died on the following months of treatment for severely increased azotemia (stage IV).

In conclusion, Darbepoetin proved effective in increasing PCV, anemic crisis potentially in 66.7% of dogs @0.5 to 0.8 μg/ kg s/c weekly till target PCV achieved. Though expensive than erythropoietin, Darbepoetin @0.5μg/kg s/c proved safe and effective in improving packed cell volume in CKD dogs as an alternative to packed RBC or whole blood transfusion. Further immunological, toxicological and clinical studies on darbepoetin therapy are warranted in a large population.

1. Grauer FG. Treatment guidelines for chronic kidney disease in dogs and cats: International Renal Interest Society Recommendations. TVPJournal.Com. 2017;41-50.
2. Polzin D. Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. J Vet Emerg Crit Care. 2013;23(2):205–215. Doi: 10.1111/vec.12034
3. Fiocchi EH, Cowgill LD, Brown DC, Markovich JE, Tucker S, Labato MA, Callan MB, et al. The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. J Vet Intern Med. 2017;31(2):476-485. Doi: 10.1111/jvim.14681
4. O'Neil DJ, Elliott J and Church DB.  Chronic kidney disease in dogs in UK veterinary practices: Prevalence, risk factors, and survival. J Vet Intern Med. 2013;27(4):814–821. Doi: 10.1111/jvim.12090
5. Cowgill LD, James KM and Levy JK. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc. 1998;212(4):521–528.
6. Bartges JW. Chronic kidney disease in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(4):669–692. Doi: 10.1016/j.cvsm.2012.04.008
7. Chakrabarti S, Syme HM, Elliott J. Clinic pathological variables predicting progression of azotemia in cats with chronic kidney disease. J Vet Intern Med. 2012;26(2):275–281. Doi: 10.1111/j.1939-1676.2011.00874.x 
8. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half‐life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290–299.